USE OF DEPAKINE CHRONOSPHERE AS A FIRST MONOTHERAPY TO TREAT EPILEPSY IN CHILDREN

Main Article Content

Zainab Ahmed Tuhaifah
Fahd Hilal Mishaan Al-Anazi
Abdulrahman Fahad Mahmaad Bin Talhah
Ahmed Hamied D Almutairi
Abdullah Abdulrahman Sulaiman Almubarak
Naif Khaluf Aqeel Alanazi

Keywords

epilepsy, children, Depakine Chronosphere, monotherapy, valproic acid

Abstract

Epilepsy is a neurological disorder characterized by recurrent seizures, affecting approximately 50 million people worldwide. In children, epilepsy presents unique challenges due to their developing brains and susceptibility to cognitive and behavioral issues. Depakine Chronosphere, a controlled-release formulation of valproic acid, has been proposed as a first-line monotherapy for pediatric epilepsy due to its efficacy and tolerability. This essay explores the use of Depakine Chronosphere in treating epilepsy in children, focusing on its pharmacological properties, clinical effectiveness, and safety profile. The methods, results, and discussions presented highlight the potential benefits of Depakine Chronosphere as a primary treatment option for pediatric epilepsy.

Abstract 185 | PDF Downloads 112

References

1. Guerrini R, Dravet C, Genton P, et al. Valproic acid as a mainstay of therapy for Dravet syndrome. In: Advances in neurology. 89th ed. Philadelphia: Lippincott Williams & Wilkins (2018). p. 641–53.
2. Mula M, Sander JW. Suicidal behavior and antiepileptic drugs in epilepsy: 2008–2010 update. Expert Opin Drug Saf 2011;10(4):543–56.
3. Jedrzejczak J, Malolepszy A, Mojs E, et al. Neuropsycholog-ical profile in children with primary generalized epilepsy. Ep-ilepsy Behav 2005;7:288–93.
4. Andrade-Machado R, . Salas-Pacheco J, Cerecedo-Zapata CM, et al. Current antiepileptic drugs in pediatric epilepsy. Bol Med Hosp Infant Mex 2016;73:380–9.
5. Brent AS, Barbara CM Jr. Antiepileptics in children with epilepsy: Clinician’s guide. Curr Treat Options Neurol 2019;21: 53.
6. González-Cuevas P, de la Torre Vázquez N, Prado A, et al. A. Neurofilament light protein and progranulin as novel markers of neurodegeneration in temporal lobe epilepsy. J Neuropathol Exp Neurol 2016;75:7.
7. Reimers A, Brodtkorb E, Sabers A. Interactions between antiepileptic drugs and hormones. Endocrine 2017;21.
8. Dekker FM, Dieleman JP, Crama SD, et al. The long-term treatment outcome of approximately 1,832 children surviving an episode of status epilepticus. Verhulst2013;1(2):200–8.
9. Wirrell EC. Treatment of pediatric epilepsy: what makes a difference? Neuropsych Dis Treat 2010;6:139.
10. Fisher RS. Depression in epilepsy: etiology, detection, implications, and treatment. Sciences2012;(8):119–24.

Most read articles by the same author(s)